Effects of hormones on 3', 5' -cyclic adenosine monophosphate in choroid plexus.
Choroid plexus of rabbit and rat was incubated for 2-30 min at 37 degrees C under 95% O2-5% CO2 in Tyrode solution containing 10 mM glucose and 1 mM theophylline with these agents: epinephrine, norepinephrine, isoproterenol, dopamine, histamine, serotonin, arginine, and lysine vasopressins, oxytocin, angiotensin, adrenocorticotropin (ACTH), beta-melanocyte-stimulating hormone, and choroid plexus peptide IIF. After incubation, tissue and medium were analyzed for 3', 5' -cyclic adenosine monophosphate (cAMP) content. Each amine or peptide was tested initially at 1,000 microng/ml. Only ACTH and serotonin affected cAMP content of rabbit choroid plexus. At 1,000 microng/ml, these agents caused a 10 and 4 times (respectively) increase in cAMP content of tissue + medium at 2-10 min with decline in content at 10-30 min. More than 90% of the increment was located in  tissue, less than 10% in medium. Minimal effective dose (MED) to cause a significant (P less than .05) accumulation of cAMP was 0.1 microng/ml (2.2 x 10(-8) M) for ACTH and 10 microng/ml (5.7 x10(-3) M) for serotonin. Only isoproterenol, epinephrine, and norepinephrine influenced cAMP content of rat choroid plexus. MED's for this effect by isoproterenol, epinephrine, and norepinephrine were .001, .01, and 10 microng/ml (4.7 x 10(-9), 5.5 x 10(-8), and 5.9 x 10(-5) M), respectively.
D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D001337:Autonomic Agents / Q000494:pharmacology*; D002831:Choroid Plexus / Q000187:drug effects / Q000378:metabolism*; D000242:Cyclic AMP / Q000378:metabolism*; D003983:Dibenzylchlorethamine / Q000494:pharmacology; D004298:Dopamine / Q000494:pharmacology; D004837:Epinephrine / Q000494:pharmacology; D006632:Histamine / Q000494:pharmacology; D066298:In Vitro Techniques; D007545:Isoproterenol / Q000494:pharmacology; D008297:Male; D009074:Melanocyte-Stimulating Hormones / Q000494:pharmacology; D009638:Norepinephrine / Q000494:pharmacology; D010121:Oxytocin / Q000494:pharmacology; D010455:Peptides / Q000494:pharmacology; D010643:Phenoxybenzamine / Q000494:pharmacology; D010907:Pituitary Hormones / Q000494:pharmacology*; D011433:Propranolol / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D012701:Serotonin / Q000494:pharmacology; D014667:Vasopressins / Q000494:pharmacology
D001337:Autonomic Agents; D010455:Peptides; D010907:Pituitary Hormones; D010643:Phenoxybenzamine; D014667:Vasopressins; D000804:Angiotensin II; D012701:Serotonin; D003983:Dibenzylchlorethamine; D010121:Oxytocin; D006632:Histamine; D000324:Adrenocorticotropic Hormone; D009074:Melanocyte-Stimulating Hormones; D011433:Propranolol; D000242:Cyclic AMP; D007545:Isoproterenol; D004298:Dopamine; D009638:Norepinephrine; D004837:Epinephrine